Journal
CLINICAL CANCER RESEARCH
Volume 28, Issue 15, Pages 3179-3181Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1078-0432.CCR-22-1137
Keywords
-
Categories
Funding
- Bristol-Myers Squibb
- Novartis
- Verily
Ask authors/readers for more resources
The activity of KRAS inhibitors against brain metastases is not well studied. Recent preclinical models and preliminary data from the ongoing KRYSTAL-1 phase Ib clinical trial suggest that adagrasib (MRTX849) has the potential to penetrate the central nervous system and provide control of KRAS(G12C) brain metastases.
The activity of KRAS inhibitors against brain metastases is relatively unexplored. The recent work on preclinical models and preliminary data from the ongoing KRYSTAL-1 phase Ib clinical trial support the potential of adagrasib (MRTX849) to penetrate the central nervous system and provide control of KRAS(G12C) brain metastases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
